BioSpace News Archive

Revenue for the year ended December 31, 2019 was $46.7 million, compared to $46.6 million for the year ended December 31, 2018. Net income for the year ended December 31, 2019 was $3.0 million, or $0.23 per diluted share, compared to $3.6 million, or $0.26 per diluted share, for the year ended December 31, 2018. NOGALES, Ariz., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT) , a leading manufacturer of products designed to protect people, products and environm

Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix.

Latest Connected Health Technology to Improve Collaboration Among Patients, Care Team, and Physicians

Leaders from The Permanente Federation, The SCAN Foundation and California Health Care Foundation will present “Treating the Other 1%: Americans with Unmet Needs,” a panel on March 17, 2020 at the South by Southwest® Conference in Austin, Texas.

Feb. 26, 2020 13:00 UTC Seattle Genetics to Present at the Cowen 40 th Annual Healthcare Conference BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen 40 th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Sea

Feb. 26, 2020 13:00 UTC Cadent Therapeutics to Present at the Cowen 40 th Annual Health Care Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cadent Therapeutics , a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2,

Feb. 26, 2020 13:03 UTC LOS ANGELES--( BUSINESS WIRE )-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The sNDA approval wa

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020, at 9:20 a.m. EST.

New initiative offers customers a way to attack cancer from every angle

The Parker Institute for Cancer Immunotherapy (PICI) recently announced six early career researchers awards through the Parker Scholars, Parker Bridge Fellows and Parker Senior Fellows programs